PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Paris:IPN) announced today that it has signed an agreement with Novartis for the co-promotion in France of the antihypertensive drug Exforge®. Already in partnership with Novartis since 2003 in the area of hypertension, with the co-marketing in France of Nisis® & Nisisco®, Ipsen’s new agreement strengthens the commitment of its French teams to the management of cardiovascular risk factors.
